• Je něco špatně v tomto záznamu ?

GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression

J. Pláteník, Z. Fišar, R. Buchal, R. Jirák, E. Kitzlerová, M. Zvěřová, J. Raboch,

. 2014 ; 50 (-) : 83-93.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15008462

BACKGROUND: Glycogen synthase kinase-3β (GSK3β), cAMP-response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) play critical roles in neuronal survival, synaptic plasticity and memory and participate in the pathophysiology of both depressive disorder and Alzheimer's disease (AD). METHODS: This study was designed to determine the association of GSK3β activity, CREB activity and BDNF concentration in peripheral blood of patients with AD with or without depressive symptoms and in depressive patients without AD. GSK3β activity in platelets, CREB activity in lymphocytes and BDNF concentration in plasma, platelet-rich plasma or platelets were measured in 85 AD patients (36 of whom displayed co-morbid depressive symptoms), 65 non-AD patients with depressive disorder and 96 healthy controls. AD patients were clinically assessed for stage of dementia, cognitive impairment and severity of depressive symptoms. Depressive patients were clinically assessed for severity of depression. RESULTS: We observed increased CREB activity and GSK3β activity in AD with depressive symptoms or in AD at mild stage of dementia. Decreased BDNF concentration was found in platelet-rich plasma of AD patients at moderate to severe stages of dementia or in AD without depressive symptoms. An association was revealed of the severity of cognitive impairment with the increase of GSK3β in the platelets of AD patients with mild dementia. In depressive patients, a lower concentration of phosphorylated GSK3β was associated with a higher severity of depression. Association was confirmed between severity of depression, CREB activation, and BDNF concentration in drug-naïve depressive patients. CONCLUSION: Our data demonstrated that AD is accompanied by increased CREB activity in lymphocytes and a decreased concentration of BDNF in platelet-rich plasma. The decreased BDNF concentration appears to correlate with moderate to severe stages of dementia in AD. Observation of decreased phosphorylation of GSK3β in platelets of both AD patients with depressive symptoms and depressive patients after treatment confirms the role of increased GSK3β activity in the pathophysiology of both AD and depressive disorder. Associations were confirmed between AD and platelet GSK3β activity, lymphocyte CREB activity and plasma BDNF. CREB activity and platelet BDNF concentration seems to be related to depressive disorder.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008462
003      
CZ-PrNML
005      
20171114090332.0
007      
ta
008      
150306s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pnpbp.2013.12.001 $2 doi
035    __
$a (PubMed)24334212
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pláteník, Jan $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Kateřinská 32, 121 08 Prague 2, Czech Republic.
245    10
$a GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression / $c J. Pláteník, Z. Fišar, R. Buchal, R. Jirák, E. Kitzlerová, M. Zvěřová, J. Raboch,
520    9_
$a BACKGROUND: Glycogen synthase kinase-3β (GSK3β), cAMP-response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) play critical roles in neuronal survival, synaptic plasticity and memory and participate in the pathophysiology of both depressive disorder and Alzheimer's disease (AD). METHODS: This study was designed to determine the association of GSK3β activity, CREB activity and BDNF concentration in peripheral blood of patients with AD with or without depressive symptoms and in depressive patients without AD. GSK3β activity in platelets, CREB activity in lymphocytes and BDNF concentration in plasma, platelet-rich plasma or platelets were measured in 85 AD patients (36 of whom displayed co-morbid depressive symptoms), 65 non-AD patients with depressive disorder and 96 healthy controls. AD patients were clinically assessed for stage of dementia, cognitive impairment and severity of depressive symptoms. Depressive patients were clinically assessed for severity of depression. RESULTS: We observed increased CREB activity and GSK3β activity in AD with depressive symptoms or in AD at mild stage of dementia. Decreased BDNF concentration was found in platelet-rich plasma of AD patients at moderate to severe stages of dementia or in AD without depressive symptoms. An association was revealed of the severity of cognitive impairment with the increase of GSK3β in the platelets of AD patients with mild dementia. In depressive patients, a lower concentration of phosphorylated GSK3β was associated with a higher severity of depression. Association was confirmed between severity of depression, CREB activation, and BDNF concentration in drug-naïve depressive patients. CONCLUSION: Our data demonstrated that AD is accompanied by increased CREB activity in lymphocytes and a decreased concentration of BDNF in platelet-rich plasma. The decreased BDNF concentration appears to correlate with moderate to severe stages of dementia in AD. Observation of decreased phosphorylation of GSK3β in platelets of both AD patients with depressive symptoms and depressive patients after treatment confirms the role of increased GSK3β activity in the pathophysiology of both AD and depressive disorder. Associations were confirmed between AD and platelet GSK3β activity, lymphocyte CREB activity and plasma BDNF. CREB activity and platelet BDNF concentration seems to be related to depressive disorder.
650    _2
$a senioři $7 D000368
650    _2
$a Alzheimerova nemoc $x krev $x komplikace $x psychologie $7 D000544
650    _2
$a mozkový neurotrofický faktor $x krev $7 D019208
650    _2
$a protein vázající CREB $x krev $7 D050882
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a deprese $x krev $x komplikace $x psychologie $7 D003863
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a kinasa 3 glykogensynthasy $x krev $7 D038362
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neuropsychologické testy $7 D009483
650    _2
$a psychiatrické posuzovací škály $7 D011569
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fišar, Zdeněk $u Department of Psychiatry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic. Electronic address: zfisar@lf1.cuni.cz.
700    1_
$a Buchal, Richard $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Kateřinská 32, 121 08 Prague 2, Czech Republic.
700    1_
$a Jirák, Roman $u Department of Psychiatry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic.
700    1_
$a Kitzlerová, Eva $u Department of Psychiatry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic.
700    1_
$a Zvěřová, Martina $7 ola2017969594 $u Department of Psychiatry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic.
700    1_
$a Raboch, Jiří $u Department of Psychiatry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic.
773    0_
$w MED00003930 $t Progress in neuro-psychopharmacology & biological psychiatry $x 1878-4216 $g Roč. 50, č. - (2014), s. 83-93
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24334212 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20171114090441 $b ABA008
999    __
$a ok $b bmc $g 1065735 $s 891262
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 50 $c - $d 83-93 $i 1878-4216 $m Progress in neuro-psychopharmacology & biological psychiatry $n Prog Neuropsychopharmacol Biol Psychiatry $x MED00003930
LZP    __
$a Pubmed-20150306

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...